Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma |
| |
| Authors: | Howard I. Scher Alan Yagoda Tauseef Ahmed Daniel Budman Peter Sordillo Robin C. Watson |
| |
| Affiliation: | (1) Solid Tumor Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, 10021 New York, NY, USA;(2) Department of Diagnostic Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, 10021 New York, NY, USA;(3) Department of Medicine, Cornell University Medical College, 10021 New York, NY, USA;(4) Division of Medical Oncology, North Shore University Hospital, 11021 Manhasset, NY, USA |
| |
| Abstract: | Summary A phase-II trial of 4-demethoxydaunorubicin (4-DMDR) was performed in 21 patients with advanced renal cell carcinoma. The drug had demonstrated a broader spectrum of activity with less cardiotoxicity in preclinical evaluation than the parent compound daunorubicin. The starting dose was 12.5 mg/m2, with escalations to 15 and 17.5 mg/m2 in the absence of toxicity. Myelosuppression was the primary toxicity and cardiac toxicity was not seen in four patients who received four or more doses of DMDR. No responses were seen in 19 adequately treated patients, including 14 who had received no prior therapy. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
